A large body of evidence suggests that serotoninergic antidepressants such as clomipramine, fluvoxamine, and fluoxetine are the most effective pharmacological treatments of obsessive-compulsive disorders. ' The classic biochemical theory of major depression hypothesises disturbances in serotoninergic or catecholaminergic neurotransmission, or both. Until now, however, no specific symptoms have been clearly shown to orient with a selective antidepressant.2 In addition to the depressive disorder, the underlying personality may be assessed as a possible aid to the therapeutic decision. Compulsive personality usually pre-exists in patients developing obsessive-compulsive disorder.'
We hypothesised that patients with a major depressive episode and an underlying compulsive personality would preferentially have serotoninergic depression and hence respond to a serotoninergic antidepressant such as fluvoxamine.4 Patients, methods, and results We studied 46 Comparison of changes in Hamilton depression scores over time showed significantly greater improvement in the compulsive group after eight weeks of treatment (F (3,32) = 10-65; p=00001) (figure). This difference was even more pronounced on the subscale for endogenomorphic depression (F (3,32) = 7 09; p=00009), which had already shown a significant difference between the groups after four weeks (p= 0-05). There was no significant difference between the groups in the number of reported side effects (mainly gastrointestinal; 12 patients in the compulsive group, 12 in the non-compulsive group; x2=0 01 df=1, p= 0 92). The mean final dose of fluvoxamine was 168-4 (SD 50 6)mg in the compulsive group and 179 4 (39-8)mg in the non-compulsive group (F=0-52; p= 0 48).
Comment
These results suggest that depressive patients with an underlying compulsive personality respond better 760 BMJ VOLUME 303 to a serotoninergic antidepressant such as fluvoxamine than do depressive patients without an underlying compulsive personality. This is important as the personality ofa depressive patient can easily be assessed for orientation with a selective type of compound. In the past many studies have tried to predict treatment response to selective antidepressants by using biological markers such as the concentration of neurotransmitter metabolites in urine or cerebrospinal fluid, with controversial results.) Moreover, these methods entail elaborate techniques for collecting body fluids and for assay.
Finally, our finding that depressive patients with a compulsive personality respond better to a serotoninergic antidepressant suggests some biochemical similarity in central serotonin disturbance between this subtype of depression and obsessive-compulsive disorder. have proved more effective in treating disease arising in the osteomeatal complex.' As our understanding of the key role of this complex in sinus disease increases,2 so the rationale for using nasal drops has been reasserted. Treatment regimens usually prescribe a set number of drops to each nostril, to be self administered by the patient. The assumption is that a standard dose of the drug will thus be delivered. Many patients, however, have difficulty in sensing how many drops have entered the nose. Clearly, if the therapeutic margin of the drug is narrow safety margins may be exceeded.
Betamethasone sodium phosphate is a steroid preparation used in nasal disease. It is normally prescribed as two drops twice or three times daily in each nostril with the patient in Moffat's position. The proprietary product Betnesol (Glaxo Pharmaceuticals) utilises a standard dropper nozzle mechanism that is common to all current dropper products. It is designed to provide a constant size drop. To assess the accuracy of this system we recruited a group of healthy well informed doctors as volunteers.
Subjects, methods, and results
Ten asymptomatic doctors took part. All knew of the potential side effects of betamethasone and agreed to be rigorous in the application of the drops. A preweighed proprietary bottle of the drug (Betnesol) was given to each volunteer with the instructions to instil two drops into each nostril twice a day while adopting Moffat's position. Each administration was recorded. After 14 days the records were checked, the bottles reweighed, and the total weight of drug used by each volunteer thus calculated.
Manufacturer's data describe a standard drop weight of 0025 mg betamethasone solution. To corroborate this 10 drops formed under gravity from each of five proprietary bottles were weighed, and the average weight of the 50 drops was indeed 0 025 mg. Using these data we calculated the notional average drops used daily by each volunteer (table). All 10 volunteers overused the drug, by a range of 41-338% (mean 132%). Seven volunteers reported difficulties in sensing the number of drops entering the nose.
To help further explain the overuse we examined the mechanism of drop formation. Whereas first drops under gravity formed promptly, second drops took up to three minutes to form and the tendency was to squeeze the bottle. When 50 drops from five bottles were formed by gentle squeezing the average weight was 0-033 mg, an increase over gravity drops of 32%.
Total weight of drug used and average number ofdrops used daily by 10 volunteers using betamethasone nasal drops for 14 days 
